Maintenance of Response Through up to 4 Years of Continuous Guselkumab Treatment of Psoriasis in the VOYAGE 2 Phase 3 Study

被引：0
|
作者：
Kristian Reich
April W. Armstrong
Peter Foley
Michael Song
Megan Miller
Y. K. Shen
Yin You
Chenglong Han
Kenneth B. Gordon
机构：
[1] University Medical Center Hamburg-Eppendorf,Translational Research in Inflammatory Skin Diseases, Institute for Health Services Research in Dermatology and Nursing
[2] University of Southern California,Department of Dermatology, Keck School of Medicine
[3] The University of Melbourne,Department of Medicine
[4] St. Vincent’s Hospital Melbourne and Probity Medical Research,undefined
[5] Skin Health Institute,undefined
[6] Janssen Research & Development,undefined
[7] LLC,undefined
[8] Janssen Global Services,undefined
[9] LLC,undefined
[10] Medical College of Wisconsin,undefined
来源：
American Journal of Clinical Dermatology | 2020年 / 21卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：881 / 890
页数：9
相关论文
共 50 条
  • [21] Long-Term Efficacy of Guselkumab for the Treatment of Moderate-to-Severe Psoriasis: Results from the Phase 3 VOYAGE 1 Trial Through Two Years
    Griffiths, Christopher E. M.
    Papp, Kim A.
    Kimball, Alexa B.
    Randazzo, Bruce
    Song, Michael
    Li, Shu
    Shen, Yaung-Kaung
    Blauvelt, Andrew
    JOURNAL OF DRUGS IN DERMATOLOGY, 2018, 17 (08) : 826 - 832
  • [22] Maintenance of PASI 90 response with guselkumab through 3 years (week 156) among week 28 PASI 90 responders in the VOYAGE 1 study
    Gordon, K. B.
    Foley, P.
    Leonardi, C.
    Landells, I.
    Song, M.
    Fakharzadeh, S.
    Shen, Y-K.
    Li, S.
    Langley, R.
    Reich, K.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB90 - AB90
  • [23] Five-year Maintenance of Clinical Response and Consistent Safety Profile for Guselkumab in Asian patients with Psoriasis from VOYAGE 1 and VOYAGE 2
    Kim, Byung Soo
    Jo, Seong Jin
    Youn, Sangwoong
    Reich, Kristian
    Saadoun, Carine
    Chang, Chia-Ling
    Yang, Ya-Wen
    Huang, Yu-Huei
    Tsai, Tsen-Fang
    DERMATOLOGY AND THERAPY, 2023, 13 (11) : 2721 - 2737
  • [24] Five-year Maintenance of Clinical Response and Consistent Safety Profile for Guselkumab in Asian patients with Psoriasis from VOYAGE 1 and VOYAGE 2
    Byung Soo Kim
    Seong Jin Jo
    SangWoong Youn
    Kristian Reich
    Carine Saadoun
    Chia-Ling Chang
    Ya-Wen Yang
    Yu-Huei Huang
    Tsen-Fang Tsai
    Dermatology and Therapy, 2023, 13 : 2721 - 2737
  • [25] Comparable and consistent efficacy responses with up to 3 years of guselkumab treatment in patients with moderate-to-severe plaque psoriasis regardless of prior treatment: Pooled analysis from the VOYAGE 1 and VOYAGE 2 trials
    Gordon, K.
    Guenther, L.
    Pinter, A.
    Choe, Y. -B.
    Song, M.
    Li, S.
    Fakharzadeh, S.
    Shen, Y-K.
    Tsai, T-F.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2019, 81 (04) : AB185 - AB185
  • [26] Long-term safety of guselkumab: Results from the VOYAGE 1 and VOYAGE 2 trials with up to 5 years of treatment
    Blauvelt, Andrew
    Gordon, Kenneth B.
    Griffiths, Christopher E. M.
    Papp, Kim A.
    Foley, Peter
    Song, Michael
    Miller, Megan
    Shen, Yaung-Kaung
    You, Yin
    Ramachandran, Paraneedharan
    Reich, Kristian
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB174 - AB174
  • [27] Consistent response of guselkumab treatment between Hispanic and non-Hispanic psoriasis patients: An analysis from VOYAGE 1 and VOYAGE 2
    Puig, Luis
    Wu, Jashin J.
    Ho, Vincent
    Gooderham, Melinda
    Song, Michael
    Wasfi, Yasmine
    You, Yin
    Shen, Yaung-Kaung
    Randazzo, Bruce
    Kerdel, Francisco
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2018, 79 (03) : AB87 - AB87
  • [28] Consistent response to guselkumab treatment between Hispanic and non-Hispanic patients with psoriasis: an analysis from VOYAGE 1 and VOYAGE 2
    Puig, Luis
    Wu, Jashin J.
    Gooderham, Melinda J.
    You, Yin
    Shen, Yaung-Kaung
    Randazzo, Bruce
    Kerdel, Francisco
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2021, 32 (05) : 484 - 491
  • [29] Maintenance of response after guselkumab withdrawal in patients with moderate-to-severe psoriasis: A post hoc analysis of the VOYAGE 2 trial
    Conrad, Curdin
    Koerber, Andreas
    Schaekel, Knut
    Thaci, Diamant
    Joks, Gero
    Jazra, Maria
    Wegner, Sven
    Wapenaar, Robert
    Paul, Carle
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2021, 85 (03) : AB107 - AB107
  • [30] Malignancy rates through 5 years of follow-up in patients with moderate-to-severe psoriasis treated with guselkumab: Pooled results from the VOYAGE 1 and VOYAGE 2 trials
    Blauvelt, Andrew
    Lebwohl, Mark
    Langley, Richard G.
    Rowland, Katelyn
    Yang, Ya-Wen
    Chan, Daphne
    Miller, Megan
    You, Yin
    Yu, Jenny
    Thaci, Diamant
    Foley, Peter
    Papp, Kim A.
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 89 (02) : 274 - 282
12345